UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000022197
Receipt number R000025570
Scientific Title Clinical Study of autologous blood injection for the treatment of recurrent temporomandibular joint dislocation
Date of disclosure of the study information 2016/05/09
Last modified on 2021/11/07 13:43:58

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical Study of autologous blood injection for the treatment of recurrent temporomandibular joint dislocation

Acronym

Autologous blood injection for recurrent temporomandibular joint dislocation

Scientific Title

Clinical Study of autologous blood injection for the treatment of recurrent temporomandibular joint dislocation

Scientific Title:Acronym

Autologous blood injection for recurrent temporomandibular joint dislocation

Region

Japan


Condition

Condition

Recurrent temporomandibular joint (TMJ) dislocation

Classification by specialty

Oral surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy of the autologous blood injection for the recurrent TMJ dislocation and to standardize its procedure.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

At follow-up 6 months after the procedure, there is no episode of TMJ dislocation.

Key secondary outcomes

Improvement of QOL by decreasing the frequency of TMJ dislocation.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

1) The procedure is applied under local anesthesia. The skin overlying the TMJ is scrubbed with 10% povidone iodine and local anesthesia with 1% lidocaine including 1/80000 adrenaline is given to the preauricular area.
2) The auricular fossa is located at a point 10mm anterior to the tragus of the ear and 2mm inferior to the tragal-canthal line. At this location, 21-gauge needle is inserted into the superior joint space. When the needle tip is achieved to the superior joint space, the resistance force is reduced. After confirming the needle is placed at the correct position, the joint space is flashed with 5ml of saline via T-shaped stopcock. The 21-gauge needle is left at the position, then 5 ml of blood is drawn from the patient's anticubital fossa.
3) The syringe is connected to the previous inserted needle and blood is injected-3ml in the superior joint space and 1 ml in the pericapsular tissue.
4) After completion of the injection procedures, patients are instructed to restrict their mouth opening and to eat only soft foods for 7 days.
5) In case of the relapse of TMJ dislocation, autologous blood injection can be repeated.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) The patient was diagnosed as having recurrent TMJ dislocation based on the clinical criteria of Nitzan. The patient has the episodes of condylar dislocation for several times.
2) The conservative methods including restriction of the mandibular motions with chin cap, bandage, maxillomandibular fixation, or mouth opening training based on the self-reduce TMJ dislocation were ineffective.
3) A written informed consent must be obtained by an investigator from the patient or the legally authorized representative before the procedure.

Key exclusion criteria

1) Inflammatory diseases of temporomandibular joint, such as rheumatoid arthritis, tuberculous arthritis.
2) Evidence of tumor or tumor like lesion in the TMJ.
3) Temporomandibular disorders caused by metabolic diseases, including crystal deposition diseases such as gout, pseudogout, or crystal arthritis.
4) Intercurrent facial palsy.
5) Serious concomitant systemic disorder, including malignant hypertension, history of severe cardiovascular diseases or cerebrovascular disorders within 6 months, hemorrhagic gastric ulcers, uncontrolled diabetes, apparent bleeding tendency.
6) Under anticoagulant therapy.
7) Suspicion for active infection.
8) History of serious psychiatric illness or psychiatry illness under medical treatment.
9) Others diagnosed as inapplicable cases by an investigator.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name AKIRA
Middle name
Last name SASAKI

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Division name

Department of Oral and Maxillofacial Surgery

Zip code

7008525

Address

2-5-1 Shikata-cho, Kita-ku, Okayama, Japan

TEL

086-235-6702

Email

aksasaki@md.okayama-u.ac.jp


Public contact

Name of contact person

1st name NORIE
Middle name
Last name YOSHIOKA

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Division name

Department of Oral and Maxillofacial Surgery

Zip code

7008525

Address

2-5-1 Shikata-cho, Kita-ku, Okayama, Japan

TEL

086-235-6702

Homepage URL


Email

noriy@md.okayama-u.ac.jp


Sponsor or person

Institute

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Department of Oral and Maxillofacial Surgery

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Okayama University Graduate School of Medicine, Dentistry and Phrmaceutical Sciences and Okayama University Hospital, Ethic committee

Address

Okayama shi, Kita-ku Shikata-cho 2-5-1

Tel

086-235-6938

Email

mae6605@adm.okayama-u.a.cjp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

岡山大学病院(岡山県)


Other administrative information

Date of disclosure of the study information

2016 Year 05 Month 09 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2015 Year 06 Month 23 Day

Date of IRB

2015 Year 06 Month 23 Day

Anticipated trial start date

2016 Year 05 Month 09 Day

Last follow-up date

2023 Year 05 Month 09 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 05 Month 03 Day

Last modified on

2021 Year 11 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025570


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name